Q1 2016: HIGHEST NET SALES TO DATE FOR A SINGLE QUARTER: MSEK 87.0 (68.9)

First quarter of 2016:

  · NET SALES amounted to MSEK 87.0 (68.9).
  · OPERATING PROFIT totalled MSEK 35.3 (27.3).
  · PROFIT AFTER TAX amounted to MSEK 26.9 (22.4).
  · PROFIT AFTER TAX PER SHARE was SEK 2.95 (2.45).
  · CASH FLOW amounted to MSEK 10.0 (18.5).

Significant events during the first quarter:

  · Probi Järn®, Probi’s product to increase iron absorption, was launched in
Sweden.
  · Launch of Probi’s products in Singapore.
  · Probi acquired license for new probiotic strains for food applications from
Swedish company Probac.

Significant events after the close of the period:

  · New agreement with Ipsen Pharma for the launch of Probi’s digestive health
capsules in 18 markets.

CEO COMMENTS ON THE OPERATIONS AND FUTURE DEVELOPMENT:
“The first quarter of 2016 was a new record quarter for Probi with net sales of
MSEK 87.0. This represents growth of 26%, compared with the very strong first
quarter of 2015. Adjusted for currency effects, which were minor, net sales
amounted to MSEK 85.2, representing growth of 24%. The operating margin was
slightly higher year-on-year, despite heavy reinforcement of the organisation
with some ten new recruitments in 2015. While Probi’s growth continued in the
US, other markets – including Sweden and South Korea – also contributed to the
first-quarter increase. We have high expectations of our new agreement with
Ipsen Pharma, and expect the partnership to generate considerable volumes in a
few years’ time, since it covers a number of markets with high potential that
are new for us. The agreement is of major strategic importance to Probi and our
assessment is that it could be the most comprehensive distribution agreement to
date for Probi. Although we anticipate faster growth than the overall market for
the full-year 2016, we do not expect to achieve the same percentage growth rate
as in 2015,” says Peter Nählstedt, CEO of Probi.

INVITATION TO TELECONFERENCE (SWEDISH):
Time: Wednesday, 27 April 2016 at 10:00 a.m. Tel: +46 (0)8 566 42 665.
Participants from Probi: Peter Nählstedt, CEO and Niklas Brandt, CFO. The
presentation is available at www.probi.se and www.financialhearings.com

FOR FURTHER INFORMATION, PLEASE CONTACT:
Peter Nählstedt, CEO, Probi, tel: +46 (0)46-286 89 23 or +46 (0)723-86 99 83, e
-mail: peter.nahlstedt@probi.se
Niklas Brandt, CFO, Probi, tel: +46 (0)46-286 89 26 or +46 (0)706-62 98 83, e
-mail: niklas.brandt@probi.se

This information is such that Probi AB is required to disclose in accordance
with the Swedish Securities Market Act and/or the Financial Instruments Trading
Act. The information was submitted for publication on 27 April 2016 at 8:45 a.m.

This is a translation of the Swedish version of the interim report. When in
doubt, the Swedish wording prevails.

Probi AB is a Swedish publicly traded bioengineering company that develops
effective and well-documented probiotics. Through its world-leading research,
Probi has created a strong product portfolio in the gastrointestinal health and
immune system niches. Probi’s products are available to consumers in more than
30 countries worldwide. Probi’s customers are leading food, health-product and
pharmaceutical companies in the Functional Food and Consumer Healthcare
segments. Probi had sales of MSEK 216 in 2015. The Probi share is listed on
NASDAQ OMX Stockholm, Small Cap. Probi has about 3,500 shareholders. For more
information, please visit www.probi.se.

  ·

  ·